This study is in progress, not accepting new patients
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Summary
- Eligibility
- for people ages 16 years and up (full criteria)
- Location
- at Oakland, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- ID
- NCT05680818
- Phase
- Phase 3 Autosomal Dominant Hypocalcemia Research Study
- Study Type
- Interventional
- Participants
- About 67 people participating
- Last Updated